These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 10613455

  • 1. Pre-transplant immunological profile and risk factor analysis of post-transplant lymphoproliferative disease development: the results of a nested matched case-control study. The University of Pittsburgh PTLD Study Group.
    Shpilberg O, Wilson J, Whiteside TL, Herberman RB.
    Leuk Lymphoma; 1999 Dec; 36(1-2):109-21. PubMed ID: 10613455
    [Abstract] [Full Text] [Related]

  • 2. Co-infection of Cytomegalovirus and Epstein-Barr Virus Diminishes the Frequency of CD56dimNKG2A+KIR- NK Cells and Contributes to Suboptimal Control of EBV in Immunosuppressed Children With Post-transplant Lymphoproliferative Disorder.
    Lam JKP, Azzi T, Hui KF, Wong AMG, McHugh D, Caduff N, Chan KH, Münz C, Chiang AKS.
    Front Immunol; 2020 Dec; 11():1231. PubMed ID: 32625211
    [Abstract] [Full Text] [Related]

  • 3. Lymphocyte subsets may discern treatment effects in children and young adults with post-transplant lymphoproliferative disorder.
    LeVasseur R, Ganjoo J, Green M, Janosky J, Reyes J, Mazariegos G, Sindhi R.
    Pediatr Transplant; 2003 Oct; 7(5):370-5. PubMed ID: 14738297
    [Abstract] [Full Text] [Related]

  • 4. Decreased NKp46 and NKG2D and elevated PD-1 are associated with altered NK-cell function in pediatric transplant patients with PTLD.
    Wiesmayr S, Webber SA, Macedo C, Popescu I, Smith L, Luce J, Metes D.
    Eur J Immunol; 2012 Feb; 42(2):541-50. PubMed ID: 22105417
    [Abstract] [Full Text] [Related]

  • 5. Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD.
    Sebelin-Wulf K, Nguyen TD, Oertel S, Papp-Vary M, Trappe RU, Schulzki A, Pezzutto A, Riess H, Subklewe M.
    Transpl Immunol; 2007 Apr; 17(3):203-10. PubMed ID: 17331848
    [Abstract] [Full Text] [Related]

  • 6. Human leukocyte antigen type and posttransplant lymphoproliferative disorder.
    Lustberg ME, Pelletier RP, Porcu P, Martin SI, Quinion CD, Geyer SM, Caligiuri MA, Baiocchi RA.
    Transplantation; 2015 Jun; 99(6):1220-5. PubMed ID: 25427163
    [Abstract] [Full Text] [Related]

  • 7. Hepatitis C virus infection and risk of posttransplantation lymphoproliferative disorder among solid organ transplant recipients.
    Morton LM, Landgren O, Chatterjee N, Castenson D, Parsons R, Hoover RN, Engels EA.
    Blood; 2007 Dec 15; 110(13):4599-605. PubMed ID: 17855632
    [Abstract] [Full Text] [Related]

  • 8. Identifying predictive factors for posttransplant lymphoproliferative disease in pediatric solid organ transplant recipients with Epstein-Barr virus viremia.
    Weintraub L, Weiner C, Miloh T, Tomaino J, Joashi U, Benchimol C, Strauchen J, Roth M, Wistinghausen B.
    J Pediatr Hematol Oncol; 2014 Nov 15; 36(8):e481-6. PubMed ID: 24878618
    [Abstract] [Full Text] [Related]

  • 9. The Immune Response to Epstein Barr Virus and Implications for Posttransplant Lymphoproliferative Disorder.
    Martinez OM, Krams SM.
    Transplantation; 2017 Sep 15; 101(9):2009-2016. PubMed ID: 28376031
    [Abstract] [Full Text] [Related]

  • 10. Association between HLA-A1 and -A2 types and Epstein-Barr virus status of post-transplant lymphoproliferative disorder.
    Kinch A, Sundström C, Tufveson G, Glimelius I.
    Leuk Lymphoma; 2016 Oct 15; 57(10):2351-8. PubMed ID: 27104753
    [Abstract] [Full Text] [Related]

  • 11. Post-transplant lymphoproliferative disorder in pediatric heart transplant recipients.
    Manlhiot C, Pollock-Barziv SM, Holmes C, Weitzman S, Allen U, Clarizia NA, Ngan BY, McCrindle BW, Dipchand AI.
    J Heart Lung Transplant; 2010 Jun 15; 29(6):648-57. PubMed ID: 20304682
    [Abstract] [Full Text] [Related]

  • 12. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
    Schubert S, Renner C, Hammer M, Abdul-Khaliq H, Lehmkuhl HB, Berger F, Hetzer R, Reinke P.
    J Heart Lung Transplant; 2008 Jan 15; 27(1):100-5. PubMed ID: 18187094
    [Abstract] [Full Text] [Related]

  • 13. Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naïve lung transplant recipient.
    Aris RM, Maia DM, Neuringer IP, Gott K, Kiley S, Gertis K, Handy J.
    Am J Respir Crit Care Med; 1996 Dec 15; 154(6 Pt 1):1712-7. PubMed ID: 8970360
    [Abstract] [Full Text] [Related]

  • 14. [Post-transplant lymphoproliferative disease in liver transplant recipients--Merkur University Hospital single center experience].
    Filipec-Kanizaj T, Budimir J, Colić-Cvrlje V, Kardum-Skelin I, Sustercić D, Naumovski-Mihalić S, Mrzljak A, Kolonić SO, Sobocan N, Bradić T, Dolić ZM, Kocman B, Katicić M, Zidovec-Lepej S, Vince A.
    Acta Med Croatica; 2011 Sep 15; 65 Suppl 1():37-43. PubMed ID: 23126028
    [Abstract] [Full Text] [Related]

  • 15. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
    Hurwitz M, Desai DM, Cox KL, Berquist WE, Esquivel CO, Millan MT.
    Pediatr Transplant; 2004 Jun 15; 8(3):267-72. PubMed ID: 15176965
    [Abstract] [Full Text] [Related]

  • 16. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation.
    Taylor AL, Marcus R, Bradley JA.
    Crit Rev Oncol Hematol; 2005 Oct 15; 56(1):155-67. PubMed ID: 15979320
    [Abstract] [Full Text] [Related]

  • 17. Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry.
    Zimmermann H, Nitsche M, Pott C, Reinke P, Babel N, Hermann RM, Hauser IA, Hahn D, Ritgen M, Pietschmann C, Klapper W, Anagnostopoulos I, Trappe RU, German PTLD Study Group and German Lymphoma Alliance.
    Ann Hematol; 2021 Aug 15; 100(8):2043-2050. PubMed ID: 33973053
    [Abstract] [Full Text] [Related]

  • 18. Outcomes of kidney retransplantation in recipients with prior post-transplant lymphoproliferative disorder.
    Rouphael B, Lankireddy S, Lazaryan A, Kukla A, Ibrahim HN, Matas AJ, Issa N.
    Clin Transplant; 2016 Jan 15; 30(1):60-5. PubMed ID: 26497471
    [Abstract] [Full Text] [Related]

  • 19. IL-6 and IL-10 in post-transplant lymphoproliferative disorders development and maintenance: a longitudinal study of cytokine plasma levels and T-cell subsets in 38 patients undergoing treatment.
    Hinrichs C, Wendland S, Zimmermann H, Eurich D, Neuhaus R, Schlattmann P, Babel N, Riess H, Gärtner B, Anagnostopoulos I, Reinke P, Trappe RU.
    Transpl Int; 2011 Sep 15; 24(9):892-903. PubMed ID: 21668529
    [Abstract] [Full Text] [Related]

  • 20. Post-transplant lymphoproliferative disorder in adult liver transplant recipients: a South American multicenter experience.
    Mendizabal M, Marciano S, dos Santos Schraiber L, Zapata R, Quiros R, Zanotelli ML, Rivas MM, Kusminsky G, Humeres R, Alves de Mattos A, Gadano A, Silva MO.
    Clin Transplant; 2013 Sep 15; 27(4):E469-77. PubMed ID: 23758407
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.